Featured Press Releases

BD Announces the First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

BD Announces the First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

  • 08 Apr 2025

SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer...

Avenacy Enters U.S. Market with Launch of Doxycycline for Injection, USP

Avenacy Enters U.S. Market with Launch of Doxycycline for Injection, USP

Matthew Fyfe has been appointed as Chief Scientific Officer as Outrun Therapeutics expands its leadership team

Matthew Fyfe has been appointed as Chief Scientific Officer as Outrun Therapeutics expands its leadership team

UCB to acquire Candid Therapeutics, strengthening its immunology pipeline with novel T-cell engagers

UCB to acquire Candid Therapeutics, strengthening its immunology pipeline with novel T-cell engagers

Samsung Biologics introduces

Samsung Biologics introduces 'Samsung Organoids'—a novel drug screening service utilizing lab-grown human organ models to enhance oncology research

Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

  • Gandeeva Therapeutics Inc.
  • 18 Jun 2026
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

  • Merck & Co., Inc.
  • 18 Jun 2026
Avenacy Announces the U.S. Launch of Bortezomib for Injection

Avenacy Announces the U.S. Launch of Bortezomib for Injection

  • Avenacy
  • 18 Jun 2026
WISE Closes Oversubscribed €30 Million Series D Financing Round with ENEA Tech and Biomedical Joining as Strategic Investor

WISE Closes Oversubscribed €30 Million Series D Financing Round with ENEA Tech and Biomedical Joining as Strategic Investor

  • WISE S.p.A.
  • 17 Jun 2026
Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

  • Rugiet
  • 17 Jun 2026
Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

  • Bayer
  • 15 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.